This is contrary to the model proposed by Munkley et al., which hypothesized that downregulation of ESRP2 may decrease epithelial splicing pattern and prime prostate cancer cells for future development of mesenchymal phenotype. This evidence concerns the gene ESRP2 and prostate cancer.